A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy
Latest Information Update: 26 Sep 2024
At a glance
- Drugs RG 6237 (Primary) ; Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms MANATEE
- Sponsors Roche
- 15 Mar 2023 Planned number of patients changed from 180 to 259.
- 15 Mar 2023 Planned End Date changed from 15 Dec 2026 to 27 Jun 2026.
- 15 Mar 2023 Planned primary completion date changed from 15 Dec 2026 to 27 Jun 2026.